Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2016 - 2018)
Historic Long-Term Debt Repayments for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Q4 2018 value amounting to $8.1 million.
- Vertex Pharmaceuticals' Long-Term Debt Repayments rose 7655.74% to $8.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $27.9 million, marking a year-over-year increase of 4858.21%. This contributed to the annual value of $27.9 million for FY2018, which is 4858.21% up from last year.
- Latest data reveals that Vertex Pharmaceuticals reported Long-Term Debt Repayments of $8.1 million as of Q4 2018, which was up 7655.74% from $5.7 million recorded in Q3 2018.
- In the past 5 years, Vertex Pharmaceuticals' Long-Term Debt Repayments ranged from a high of $264.1 million in Q3 2014 and a low of -$272.9 million during Q4 2014
- Its 5-year average for Long-Term Debt Repayments is $5.3 million, with a median of $4.8 million in 2017.
- Per our database at Business Quant, Vertex Pharmaceuticals' Long-Term Debt Repayments tumbled by 1884587.91% in 2014 and then surged by 1342680.41% in 2016.
- Quarter analysis of 5 years shows Vertex Pharmaceuticals' Long-Term Debt Repayments stood at -$272.9 million in 2014, then skyrocketed by 107.21% to $19.7 million in 2015, then plummeted by 78.31% to $4.3 million in 2016, then rose by 7.97% to $4.6 million in 2017, then surged by 76.56% to $8.1 million in 2018.
- Its Long-Term Debt Repayments stands at $8.1 million for Q4 2018, versus $5.7 million for Q3 2018 and $4.9 million for Q2 2018.